Instil Bio, Inc. (Nasdaq: TIL) reported its financial results for the third quarter of 2026 on November 16, 2026. The company reported a net loss of $4.2 million for the quarter ended September 30, 2026, compared to a net loss of $13.6 million for the same period in 2025.
For the nine months ended September 30, 2026, the company recorded a net loss of $13.0 million, a reduction from the $63.5 million net loss reported for the first nine months of 2025.
In terms of expenses, research and development costs were $0.2 million for the third quarter of 2026 and $1.2 million for the nine months ended September 30, 2026. General and administrative expenses totaled $5.8 million for the quarter and $17.5 million for the nine months. The company also reported a reversal of restructuring costs of $0.1 million and a restructuring charge of $1.1 million for the nine months ended September 30, 2026.
The company’s cash position as of September 30, 2026, was approximately $67.1 million. This total included $2.5 million in cash and cash equivalents, $0.4 million in restricted cash, $59.5 million in marketable securities, and $4.6 million in long-term investments. The company stated that this cash balance is expected to fund its operating plan through 2027.
Instil Bio also disclosed that it had identified errors in previously issued financial statements regarding property taxes on its Tarzana, California facility and the presentation of tenant reimbursements. The company stated that these errors were not material to any previously issued financial statements and that no prior filing is being amended.